Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference Read more about Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA Read more about Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
Supernus Announces Second Quarter 2024 Financial Results Read more about Supernus Announces Second Quarter 2024 Financial Results
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device Read more about Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 Read more about Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference Read more about Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy Read more about Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures Read more about Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
Supernus Announces First Quarter 2024 Financial Results Read more about Supernus Announces First Quarter 2024 Financial Results
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story Read more about Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story